MRICD ClearPoint Neuro Inc

MRI Interventions to Present at Sidoti Conference

MRI Interventions to Present at Sidoti Conference

IRVINE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (NYSE American: MRIC) today announced that Chief Executive Officer Joe Burnett will present at the at the Sidoti Fall Investor Conference on Wednesday, September 25, 2019. The event will be held at the Grand Hyatt Hotel in New York, New York. Mr. Burnett will conduct a group presentation at 3:20 p.m. Eastern time and will be available to meet with interested parties throughout the day.

Those parties wishing to schedule a meeting should contact their Sidoti & Co. sales representative or MRI Interventions’ Investor Relations at .

About MRI Interventions, Inc.

MRI Interventions is a leading platform company for MRI-guided neurosurgery procedures, including deep-brain stimulation, ablation, aspiration, biopsy, and gene therapy delivery. The ClearPoint Neuro Navigation System is FDA cleared and CE marked, and is installed in more than 55 surgical centers in the U.S. To date, nearly 3,000 procedures have been performed leveraging the sub-millimetric accuracy of the ClearPoint platform. For more information, please visit .

Forward-Looking Statements

Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the company’s ClearPoint Neuro Navigation System products; the company’s ability to market, commercialize and achieve broader market acceptance for the company’s ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the company’s cash resources. More detailed information on these and additional factors that could affect the company’s actual results are described in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2018 and the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2019, both of which have been filed with the Securities and Exchange Commission.

Contact Information:

Matt Kreps, Darrow Associates Investor Relations

(214) 597-8200

EN
12/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ClearPoint Neuro Inc

 PRESS RELEASE

ClearPoint Neuro Reports Second Quarter 2020 Results

ClearPoint Neuro Reports Second Quarter 2020 Results Revenue Reaches $2.5 million Amid COVID-19 Pandemic IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its second fiscal quarter and six months ended June 30, 2020. Financial Results – Three Months Ended June 30, 2020 Total revenues for the quarter were approximately $2.5 million and $2.6 million for the three months ended June 30, 2020 and 2019, respectively, a decrease of 5%. Functional neurosurgery revenue, which consists of disposable p...

 PRESS RELEASE

ClearPoint Neuro to Announce Second Quarter 2020 Results on August 12

ClearPoint Neuro to Announce Second Quarter 2020 Results on August 12 Release and Call After Market Close IRVINE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 second quarter, which ended June 30, 2020, on Wednesday, August 12, 2020 after the market close. The Company will subsequently conduct a conference call and webcast that day to review its results at 4:30 p.m. Eastern (1:30 p.m. Pacific). Investors and analysts who would like to participate in the conference call ...

 PRESS RELEASE

ClearPoint Neuro Reports First Quarter 2020 Results

ClearPoint Neuro Reports First Quarter 2020 Results Company Provides Update on Effects of COVID-19 Pandemic IRVINE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its first fiscal quarter ended March 31, 2020. Total revenues were approximately $3.1 million and $2.5 million for the three months ended March 31, 2020 and 2019, respectively, an increase of 26% year-over-year. Functional neurosurgery revenue, which consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased...

 PRESS RELEASE

Corrected: ClearPoint Neuro to Announce First Quarter 2020 Results on ...

Corrected: ClearPoint Neuro to Announce First Quarter 2020 Results on May 12 Release and Call After Market Close IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close. The Company will subsequently conduct a conference call and webcast that day to review its results at 4:30 p.m. Eastern (1:30 p.m. Pacific). Investors and analysts who would like to participate in the conference call...

 PRESS RELEASE

ClearPoint Neuro to Announce First Quarter 2020 Results on May 12

ClearPoint Neuro to Announce First Quarter 2020 Results on May 12 Release and Call After Market Close IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada. Callers should dial in at least 5 minutes ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch